Sridar, C., Kenaan, C., & Hollenberg, P. F. (2012). Inhibition of Bupropion Metabolism by Selegiline: Mechanism-Based Inactivation of Human CYP2B6 and Characterization of Glutathione and Peptide Adducts. The American Society for Pharmacology and Experimental Therapeutics.
Citação norma ChicagoSridar, Chitra, Cesar Kenaan, and Paul F. Hollenberg. Inhibition of Bupropion Metabolism By Selegiline: Mechanism-Based Inactivation of Human CYP2B6 and Characterization of Glutathione and Peptide Adducts. The American Society for Pharmacology and Experimental Therapeutics, 2012.
Citação norma MLASridar, Chitra, Cesar Kenaan, and Paul F. Hollenberg. Inhibition of Bupropion Metabolism By Selegiline: Mechanism-Based Inactivation of Human CYP2B6 and Characterization of Glutathione and Peptide Adducts. The American Society for Pharmacology and Experimental Therapeutics, 2012.